1-7 of 7
Jeremy Ross
Close
Sort by
Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3131.
https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131
Published: 2017
Journal Articles

A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

Jenny Wu, Jeremy Ross, Franklin V. Peale, Jr., John D Shaughnessy, Jr., PhD, Ryan K Van Laar, PhD, Gareth J Morgan, MD PhD, Jeffrey M Venstrom, Elizabeth A. Punnoose, PhD
Journal: Blood
Blood (2016) 128 (22): 5613.
https://doi.org/10.1182/blood.V128.22.5613.5613
Published: 2016
Journal Articles

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Shaji Kumar, MD, Ravi Vij, MD, Jonathan L. Kaufman, MD, Joseph Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, Cristina Gasparetto, MD, Martine Amiot, Philippe Moreau, Stefanie Alzate, Jeremy Ross, Martin Dunbar, Tu Xu, Suresh Agarwal, Joel Leverson, Paulo Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood
Blood (2016) 128 (22): 488.
https://doi.org/10.1182/blood.V128.22.488.488
Published: 2016
Journal Articles

Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, Asher A. Chanan-Khan, MD, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, MD, Shaji Kumar, MD, Cyrille Touzeau, Jaclyn Cordero, Jeremy Ross, Wijith Munasinghe, Jia Jia, Ahmed H. Salem, Joel Leverson, Paulo Maciag, Maria Verdugo, Simon J. Harrison
Journal: Blood
Blood (2016) 128 (22): 975.
https://doi.org/10.1182/blood.V128.22.975.975
Published: 2016
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Shaji K. Kumar, MD, Ravi Vij, MD MBA, Jonathan L. Kaufman, MD, Joseph R. Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MDPhD, Philippe Moreau, MD, Martine Amiot, PhD, Stefanie Alzate, MS, Lura Morris, BA, Jeremy Ross, PhD, Martin Dunbar, DrPH, Ming Zhu, PhD, Paulo Maciag, MD, Suresh Agarwal, PhD, Joel Leverson, PhD, Sari Heitner Enschede, MD, Rod A. Humerickhouse, MD PhD, Cyrille Touzeau, MD
Journal: Blood
Blood (2015) 126 (23): 4219.
https://doi.org/10.1182/blood.V126.23.4219.4219
Published: 2015
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Philippe Moreau, MD PhD, Asher Chanan-Khan, MD, Andrew W. Roberts, MBBS, PhD, Amit B. Agarwal, MDPhD, Thierry Facon, Shaji Kumar, MD, Cyrille Touzeau, MD, David Darden, MS, Lura Morris, BA, Jeremy Ross, PhD, Ahmed H Salem, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Joel Leverson, PhD, Paulo Maciag, MD, Sari Heitner Enschede, MD, Maria Verdugo, MD, Rod A. Humerickhouse, MD PhD, Simon Harrison, MD
Journal: Blood
Blood (2015) 126 (23): 3038.
https://doi.org/10.1182/blood.V126.23.3038.3038
Published: 2015
Journal Articles

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Jeremy Ross, PhD, Martine Amiot, PhD, Brenda Chyla, PhD, Lisa Roberts-Rapp, Rasna Goswami, Sun Yan, Xin Huang, Anahita Bhathena, Sari Heitner Enschede, MD, Paulo Maciag, MD, Rod A. Humerickhouse, MD PhD, Evelyn McKeegan
Journal: Blood
Blood (2015) 126 (23): 2975.
https://doi.org/10.1182/blood.V126.23.2975.2975
Published: 2015